In breast cancer (BC), the checkpoint inhibitor anti‐PD‐L1, which blocks immunosuppressive effects of tumors on T cells, is available only for patients with triple‐negative PD‐L1–positive advanced BC.1 Here, CD274 is linked to breast carcinoma.